Price
75.08
+1.99% UC52W Range
Market Cap
₹28.09 Cr
Traded: ₹0.01 Cr (0.03%) 0.0x
Free Float: ₹10.78 Cr (0.09% of FF traded)
Volume · 60D trend
1.25 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | -- | -- | -- | -- | -- | -- |
| Sales | -- | -14.0% | -8.0% | -- | -57.0% | Stable |
| Profit | -- | -- | -- | -- | -308.0% | -- |
| Return | -- | -6.0% | +14.0% | +20.0% | -- | Accelerating |
Quarterly Results
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3 | 4 | 3 | 2 | 5 | 6 | 9 | 8 | 4 | 1 | 4 | 1 | 6 |
| Expenses | 5 | 5 | 4 | 2 | 5 | 6 | 9 | 7 | 5 | 2 | 5 | 2 | 6 |
| Operating Profit | -2 | -0 | -2 | -0 | -1 | 0 | 0 | 1 | -1 | -1 | -1 | -1 | 1 |
| OPM % | -46.8% | -4.6% | -62.9% | -12.9% | -11.6% | 1.8% | 2.2% | 6.5% | -18.8% | -86.5% | -18.9% | -46.4% | 13.2% |
| Other Income | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -2 | -1 | -2 | -1 | -2 | -0 | -0 | 0 | -1 | -2 | -1 | -1 | 0 |
| Tax % | -74.5% | 0.0% | 0.0% | 0.0% | -16.8% | 0.0% | 0.0% | 0.0% | 6.6% | 0.0% | 0.0% | 0.0% | 48.5% |
| Net Profit | -1 | -1 | -2 | -1 | -1 | -0 | -0 | 0 | -1 | -2 | -1 | -1 | 0 |
| Exceptional Items | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Rs) | -1.6 | -1.9 | -5.6 | -2.0 | -4.0 | -1.0 | -0.6 | 0.0 | -3.9 | -4.7 | -3.7 | -3.1 | 0.5 |
| Sales Growth (YoY) | -31.5% | -31.1% | -72.7% | -75.2% | 13.4% | 372.2% | 128.0% | 458.6% | -33.2% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -23.6% | 71.2% | 30.4% | -59.8% | -23.1% | -32.3% | 18.7% | 83.6% | 220.3% | -67.3% | 190.7% | -78.1% | -- |
| OP Growth (YoY) | -176.8% | -281.8% | -895.0% | -149.0% | 30.0% | 109.6% | 126.0% | 178.5% | -195.2% | -- | -- | -- | -- |
| OP Growth (QoQ) | -675.0% | 87.4% | -536.0% | 55.4% | -609.1% | -45.0% | -60.8% | 163.8% | 30.4% | -49.4% | -18.5% | -177.4% | -- |
| Profit Growth (YoY) | -38.1% | -87.2% | -845.5% | -7700.0% | 71.0% | 77.7% | 83.9% | 100.8% | -952.9% | -200.6% | -95.7% | 10.6% | -- |
| EPS Growth (YoY) | 61.1% | -87.5% | -842.4% | -6866.7% | -2.6% | 77.8% | 83.9% | 101.0% | -962.2% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 20.5% | 64.9% | -173.9% | 49.0% | -282.7% | -76.3% | -2066.7% | 100.8% | 17.1% | -27.9% | -16.2% | -800.0% | -- |
| OP Margin | -46.8% | -4.6% | -62.9% | -12.9% | -11.6% | 1.8% | 2.2% | 6.5% | -18.8% | -86.5% | -18.9% | -46.4% | 13.2% |
| Net Margin | -17.5% | -16.9% | -82.2% | -39.2% | -30.9% | -6.2% | -2.4% | 0.1% | -34.0% | -131.6% | -33.7% | -84.3% | 2.7% |
| Material Cost % | 98.0% | 72.0% | 101.0% | 50.0% | 77.0% | 73.0% | 80.0% | 75.0% | 77.0% | 47.0% | 67.0% | 31.0% | 56.0% |
| Employee Cost % | 13.0% | 18.0% | 26.0% | 32.0% | 12.0% | 13.0% | 9.0% | 10.0% | 12.0% | 63.0% | 21.0% | 51.0% | 9.0% |
| P/S | 2.32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Newspaper publication with respect to Corrigendum to EGM Notice
Corrigendum to the EGM Notice dated 8th June 2026
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pradeep Ramniklal Gosalia
Fedex Securities Pvt Ltd ("Manager to the Offer") has submitted to BSE a copy of Draft Letter of Offer for the attention of the Public Shareholders of Parmax Pharma Ltd ("Target Company").
The Exchange has received the disclosure under Regulation 18(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sunil Chinubhai Shah & Dhiren Shah
The Exchange has received the disclosure under Regulation 18(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dhiren Chandulal Shah, Sunil Chinubhai Shah & PACs
Fedex Securities Pvt Ltd ("Manager to the Offer") has submitted to BSE a copy of Detailed Public Statement in terms of Regulations 3(1) and 4 read with Regulations 13(4), 14 (3) and 15(2) ....
Regarding Notice of EGM and E-voting
Fedex Securities Pvt Ltd ("Manager to the Offer") has submitted to BSE a copy of Public Announcement under Regulation 3(1) And Regulation 4 Read with Regulation 13, Regulation 14 And Regulation ....
Share purchase agreement and Public Announcement
Notice of EGM scheduled to be held on July 02, 2026
Issue of Shares and Warrants on Preferential basis pursuant to SEBI ICDR Regulations
Results for Financial Results for Quarter and Financial Year ended March 31, 2026
Reschedule of Boar Meeting and Outcome of Board Meeting
Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/06/2026 ,inter alia, to consider and approve Fund raising
Proceedings of EGM held on May 27, 2026
Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/06/2026 ,inter alia, to consider and approve audited financial results for ....
Scrutinizer Report
Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve audited financial results of ....
Notice of Extra-ordinary General Meeting of the Company scheduled to be held on May 27, 2026
Re-appointment of Mr. Umang Gosalia as a Managing Director of the Company
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
RTA Compliance certificate for Quarter ended March 31, 2026
Closure of trading window
Appointment of Ms. Bhakti Aghera as a Company Secretary
Outcome of Board meeting for Financial Results
Unaudited Financial results for quarter and Nine months ended 31.12.2025
Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 ,inter alia, to consider and approve Unaudited Financial results for ....
RTA Certificate under regulation 74(5) of SEBI DP Regulations for quarter ended December 31, 2025
Closure of trading window
The Board Meeting was initially rescheduled on November 15, 2025 and thenafter on today i.e. November 17, 2025 hence Board has approved the Unaudited Financial statements for quarter and ....
The Board meeting for approval of Financial statements was rescheduled initially on November 15, 2025 and thenafter on today i.e. November 17, 2025. The Board has approved the unaudited ....
Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/11/2025 ,inter alia, to consider and approve Reschedule of Board Meeting supposed ....
Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve For approval of Unaudited Financial ....
Compliance certificate under Reg 74(5) of SEBI (DP) Regulations
Voting Result along with scrutinizer report for 31st AGM of the COmpany
Closure of trading window
Proceedings of 31st AGM of the Company
Newspaper Advertisement with respect to 31st Annual General Meeting of the company
Annual Report for FY 2024-25
Notice of Thirty first annual general meeting of the Comapny
Appointment of Secretarial auditors
Due to typographical error in covering page resubmitting financial statements for quarter ended 30th June 2025
Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2025 ,inter alia, to consider and approve Board meeting to be held for ....
Compliance certificate under Reg 74(5) of SEBI (DP) Regulations
Resignation of Company Secretary and Compliance officer of the Company
Closure of trading window
in accordance with amendments to SEBI (LODR) (third amendment) Regulations, 2024 read with SEBI circular No. SEBI/HO/CFD/CFD-PoD2/ CIR/P/2024/185 dated 31.12.2024. the integrated filing ....
The board of directors of the company has its meeting held today inter alia considered and approved financial results for the quarter and financial year ended on 31st March, 2025 along ....
The board of directors of Parmax Pharma Limited has its meeting held today inter alia considered and approved the Audited financial statements of the company for the quarter and year ended ....